Kynmobi (Apomorphine Hydrochloride Hemihydrate)

Apomorphine, the active ingredient in Kynmobi, directly activates dopamine D1 and D2 receptors in the brain. This mimics the action of natural dopamine, quickly restoring motor function during periods when endogenous dopamine levels are insufficient.

The specific dose of Kynmobi is determined by the prescribing physician based on the individual patient's clinical condition, response, and tolerability. Dosage adjustments are made under medical supervision to achieve optimal control of OFF episodes.

Safety data for Kynmobi in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Kynmobi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then provide pricing, availability, shipping details (including cold‑chain if needed) and assist with import documentation.

Kynmobi provides rapid, sublingual delivery of apomorphine, offering quicker onset of action compared with oral levodopa formulations. Unlike injectable apomorphine, the sublingual tablet is non‑invasive, making it convenient for patients who need prompt relief from OFF episodes without injections.

Kynmobi should be stored at ambient temperature, below 25 °C. Keep the tablets in the original blister pack, protect them from moisture, direct sunlight and excessive heat to maintain stability and potency.

Kynmobi is taken as a sublingual tablet placed under the tongue. The tablet should be allowed to dissolve completely without swallowing, and the patient should remain upright for several minutes to ensure optimal absorption.

Serious risks include severe hypotension, syncope, hallucinations, impulse control disorders, and rare cardiac arrhythmias. Patients should be monitored closely, especially during dose initiation, and any concerning symptoms should be reported to a healthcare provider immediately.

Kynmobi is contraindicated in individuals with known hypersensitivity to apomorphine or any tablet excipients, and in patients with uncontrolled cardiovascular disease or severe psychiatric conditions where dopamine agonists could exacerbate symptoms.